Clinical pharmacokinetics of ibuprofen arginine

Dario Cattaneo, Emilio Clementi

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Currently, several ibuprofen compounds are available on the market, differing in terms of pharmaceutical composition that influence the pharmacokinetic profile and eventually the onset of drug action. This review will mainly deal with the clinical pharmacokinetics of ibuprofen arginine, an alternative formulation specifically designed to improve the absorption of ibuprofen. Indeed, available data from studies in healthy volunteers have consistently shown that the formulation of ibuprofen arginine is characterized by prompt absorption of ibuprofen as compared to the conventional formulation at all tested doses with higher peak plasma concentration and lower Tmax values. This trend has been confirmed also in studies dealing with chiral ibuprofen pharmacokinetics. Most importantly, the shortening in the absorption time observed either with racemic mixture or with the S(+)-enantiomer of ibuprofen arginine did not imply a faster drug elimination eventually leading to inadequate daily drug exposure, as documented by T1/2 and AUC values being comparable to those measured with the free acid form. Taken together, the pharmacokinetic/dynamic characteristics of ibuprofen arginine can be considered particularly favorable for several clinical conditions, such as moderate/severe pain, in which a rapid pharmacologic effect is required.

Original languageEnglish
Pages (from-to)239-245
Number of pages7
JournalCurrent Clinical Pharmacology
Volume5
Issue number4
DOIs
Publication statusPublished - 2010

Fingerprint

Ibuprofen
Pharmacokinetics
Pharmaceutical Preparations
Area Under Curve
Healthy Volunteers
Pain
Acids
ibuprofen arginine

Keywords

  • Arginine
  • Chirality
  • Drug absorption
  • Ibuprofen
  • Pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Clinical pharmacokinetics of ibuprofen arginine. / Cattaneo, Dario; Clementi, Emilio.

In: Current Clinical Pharmacology, Vol. 5, No. 4, 2010, p. 239-245.

Research output: Contribution to journalArticle

Cattaneo, Dario ; Clementi, Emilio. / Clinical pharmacokinetics of ibuprofen arginine. In: Current Clinical Pharmacology. 2010 ; Vol. 5, No. 4. pp. 239-245.
@article{f101b08d041945329dd76b9b1be6b865,
title = "Clinical pharmacokinetics of ibuprofen arginine",
abstract = "Currently, several ibuprofen compounds are available on the market, differing in terms of pharmaceutical composition that influence the pharmacokinetic profile and eventually the onset of drug action. This review will mainly deal with the clinical pharmacokinetics of ibuprofen arginine, an alternative formulation specifically designed to improve the absorption of ibuprofen. Indeed, available data from studies in healthy volunteers have consistently shown that the formulation of ibuprofen arginine is characterized by prompt absorption of ibuprofen as compared to the conventional formulation at all tested doses with higher peak plasma concentration and lower Tmax values. This trend has been confirmed also in studies dealing with chiral ibuprofen pharmacokinetics. Most importantly, the shortening in the absorption time observed either with racemic mixture or with the S(+)-enantiomer of ibuprofen arginine did not imply a faster drug elimination eventually leading to inadequate daily drug exposure, as documented by T1/2 and AUC values being comparable to those measured with the free acid form. Taken together, the pharmacokinetic/dynamic characteristics of ibuprofen arginine can be considered particularly favorable for several clinical conditions, such as moderate/severe pain, in which a rapid pharmacologic effect is required.",
keywords = "Arginine, Chirality, Drug absorption, Ibuprofen, Pharmacokinetics",
author = "Dario Cattaneo and Emilio Clementi",
year = "2010",
doi = "10.2174/157488410793352012",
language = "English",
volume = "5",
pages = "239--245",
journal = "Current Clinical Pharmacology",
issn = "1574-8847",
publisher = "Bentham Science Publishers B.V.",
number = "4",

}

TY - JOUR

T1 - Clinical pharmacokinetics of ibuprofen arginine

AU - Cattaneo, Dario

AU - Clementi, Emilio

PY - 2010

Y1 - 2010

N2 - Currently, several ibuprofen compounds are available on the market, differing in terms of pharmaceutical composition that influence the pharmacokinetic profile and eventually the onset of drug action. This review will mainly deal with the clinical pharmacokinetics of ibuprofen arginine, an alternative formulation specifically designed to improve the absorption of ibuprofen. Indeed, available data from studies in healthy volunteers have consistently shown that the formulation of ibuprofen arginine is characterized by prompt absorption of ibuprofen as compared to the conventional formulation at all tested doses with higher peak plasma concentration and lower Tmax values. This trend has been confirmed also in studies dealing with chiral ibuprofen pharmacokinetics. Most importantly, the shortening in the absorption time observed either with racemic mixture or with the S(+)-enantiomer of ibuprofen arginine did not imply a faster drug elimination eventually leading to inadequate daily drug exposure, as documented by T1/2 and AUC values being comparable to those measured with the free acid form. Taken together, the pharmacokinetic/dynamic characteristics of ibuprofen arginine can be considered particularly favorable for several clinical conditions, such as moderate/severe pain, in which a rapid pharmacologic effect is required.

AB - Currently, several ibuprofen compounds are available on the market, differing in terms of pharmaceutical composition that influence the pharmacokinetic profile and eventually the onset of drug action. This review will mainly deal with the clinical pharmacokinetics of ibuprofen arginine, an alternative formulation specifically designed to improve the absorption of ibuprofen. Indeed, available data from studies in healthy volunteers have consistently shown that the formulation of ibuprofen arginine is characterized by prompt absorption of ibuprofen as compared to the conventional formulation at all tested doses with higher peak plasma concentration and lower Tmax values. This trend has been confirmed also in studies dealing with chiral ibuprofen pharmacokinetics. Most importantly, the shortening in the absorption time observed either with racemic mixture or with the S(+)-enantiomer of ibuprofen arginine did not imply a faster drug elimination eventually leading to inadequate daily drug exposure, as documented by T1/2 and AUC values being comparable to those measured with the free acid form. Taken together, the pharmacokinetic/dynamic characteristics of ibuprofen arginine can be considered particularly favorable for several clinical conditions, such as moderate/severe pain, in which a rapid pharmacologic effect is required.

KW - Arginine

KW - Chirality

KW - Drug absorption

KW - Ibuprofen

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=79952279008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952279008&partnerID=8YFLogxK

U2 - 10.2174/157488410793352012

DO - 10.2174/157488410793352012

M3 - Article

VL - 5

SP - 239

EP - 245

JO - Current Clinical Pharmacology

JF - Current Clinical Pharmacology

SN - 1574-8847

IS - 4

ER -